La vendita allo scoperto per Global Medical REIT dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Global Medical REIT. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Global Medical REIT (NYSE:GMRE) Azioni, Report sulle vendite allo scoperto

Global Medical REIT

Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.

Hand,Choosing,Wooden,House,Model,,Mortgage,And,Real,Estate,Property

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

GMRE

Real estate sotto pressione: un indicatore tecnico svela tre candidati pronti al rimbalzo. Ecco i nomi da tenere d&#39;occhio.

3 azioni ipervendute: l&#39;occasione che pochi stanno vedendo

Global Medical REIT Inc

Global Medical REIT Inc. Series A Cumulative Redeemable Preferred Stock

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Global Medical REIT Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, Global Medical REIT reported mixed first-quarter financial results. Jeffrey M. Busch, Chairman, Chief Executive Officer and President stated, &#8220;During the first quarter, we continued to deliver steady results supported by the high quality of our portfolio and stability of our tenant base.&#8221; The company's stock fell around 13% over the past five days and has a 52-week low of $6.58.</li>
<li>RSI Value: 27.3</li>
<li>GMRE Price Action: Shares of Global Medical REIT fell 1.3% to close at $6.70 on Tuesday.</li>
<li>Edge Stock Ratings: 21.25 Momentum score with Value at 50.58. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/GMRE"><img loading="lazy" decoding="async" width="492" height="177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15035949/image-172.png" alt="" class="wp-image-916113" style="width:367px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15035949/image-172.png 492w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15035949/image-172-300x108.png 300w" sizes="(max-width: 492px) 100vw, 492px" /></a></figure>
<h3 class="wp-block-heading">Office Properties Income Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPI#NASDAQ">OPI</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, Trinseo reported worse-than-expected first-quarter sales results. Frank Bozich, President and Chief Executive Officer of Trinseo, said, &#8220;Core business results in the first quarter were in line with expectations, and sequentially higher due to prior quarter customer destocking and seasonality. Despite persistent market weakness, the first quarter was Trinseo&#8217;s 7th consecutive quarter of year-over-year Adjusted EBITDA improvement driven by the various management actions we took early in this industry downturn.&#8221; The company's stock fell around 31% over the past month and <a href="https://www.benzinga.com/quote/OPI">has a 52-week low</a> of $0.25.</li>
<li>RSI Value: 25.6</li>
<li>OPI Price Action: Shares of Office Properties Income Trust fell 7.5% to close at $0.25 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in OPI <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515">stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="925" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040127/image-173.png" alt="" class="wp-image-916114" style="width:621px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040127/image-173.png 925w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040127/image-173-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040127/image-173-768x687.png 768w" sizes="(max-width: 925px) 100vw, 925px" /></a></figure>
<h3 class="wp-block-heading">Healthpeak Properties Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>)</h3>
<ul class="wp-block-list">
<li>On April 24, Healthpeak Properties posted better-than-expected quarterly sales. The company's stock fell around 10% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/DOC">low of $16.90</a>.</li>
<li>RSI Value: 25.7</li>
<li>DOC Price Action: Shares of Healthpeak Properties fell 1.6% to close at $16.97 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515">DOC shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="881" height="816" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040214/image-174.png" alt="" class="wp-image-916116" style="width:594px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040214/image-174.png 881w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040214/image-174-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15040214/image-174-768x711.png 768w" sizes="(max-width: 881px) 100vw, 881px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a></li>
</ul>
Photo via Shutterstock

Top 3 Real Estate Stocks You'll Regret Missing This Quarter

WIIM

Global Medical REIT shares are trading lower after the company reported mixed Q1 financial results. Also, Baird lowered its price target on the stock from $10 to $9.

Baird analyst Amanda Sweitzer maintains Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) with a Neutral and lowers the price target from $10 to $9.

Price Target

Analyst Ratings

Baird Maintains Neutral on Global Medical REIT, Lowers Price Target to $9

Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) affirms FY2025 FFO guidance from $0.89-$0.93 to $0.89-$0.93 vs $0.85 analyst estimate..

Guidance

Global Medical REIT Affirms FY2025 AFFO per share Guidance of $0.89-$0.93 vs $0.85 Est

Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent. This is a 4.35 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $34.59 million which missed the analyst consensus estimate of $35.48 million by 2.49 percent. This is a 1.35 percent decrease over sales of $35.07 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Global Medical REIT Q1 FFO $0.22 Beats $0.20 Estimate, Rental revenue $34.59M Miss $35.48M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Citizens Capital Markets analyst Aaron Hecht reiterates Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) from Market Perform to Market Perform.

Reiteration

Citizens Capital Markets Reiterates Market Perform on Global Medical REITto Market Perform

Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent. This is a 4.35 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $34.95 million which beat the analyst consensus estimate of $34.63 million by 0.94 percent. This is a 6.14 percent increase over sales of $32.93 million the same period last year.

Global Medical REIT Q4 FFO $0.22 Beats $0.20 Estimate, Sales $34.95M Beat $34.63M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

ALEX

ALHC

ALKT

ALTM

AMBP

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

Chief Executive Officer Transition Expected in 2025
Mr. Busch to Remain on Board of Directors as Non-Executive Chairman
Lori Wittman Appointed Lead Independent Director Effective January 1, 2025
Global Medical REIT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) (the "Company" or "GMRE"), a net-lease medical real estate investment trust (REIT) that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems, today announced that as part of the Company's succession planning efforts, the Board of Directors (the "Board") has reached an agreement with Mr. Jeffrey Busch, Chairman of the Board of Directors and Chief Executive Officer ("CEO") of the Company, regarding Mr. Busch's transition from service as CEO and with anticipated continuation as a member of the Board.
Pursuant to the agreement with Mr. Busch, his service as CEO will end on the first to occur of (i) the date that a successor CEO has been appointed by the Board pursuant to the Company's CEO succession plan or (ii) June 30, 2025 (such date that is first to occur, the "Succession Date").

Management

Global Medical REIT Announces Succession Plan; CEO Transition Expected In 2025; Jeffrey Busch To Remain On Board Of Directors As Non-Executive Chairman; Lori Wittman Appointed Lead Independent Director Effective January 1, 2025

Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent. This is a 4.35 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $34.175 million which missed the analyst consensus estimate of $34.645 million by 1.36 percent. This is a 3.70 percent decrease over sales of $35.487 million the same period last year.

Global Medical REIT Q3 2024 FFO $0.22 Beats $0.20 Estimate, Sales $34.175M Miss $34.645M Estimate

Berenberg analyst Kai Klose initiates coverage on Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) with a Buy rating and announces Price Target of $11.75.

Initiation

Berenberg Initiates Coverage On Global Medical REIT with Buy Rating, Announces Price Target of $11.75

Alliance Global Partners initiates coverage on Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) with a Buy rating and announces Price Target of $12.

Alliance Global Partners Initiates Coverage On Global Medical REIT with Buy Rating, Announces Price Target of $12

B. Riley Securities analyst Bryan Maher maintains Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) with a Buy and lowers the price target from $11 to $10.

B. Riley Securities Maintains Buy on Global Medical REIT, Lowers Price Target to $10

Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.21 by 9.52 percent. This is unchanged from the same period last year. The company reported quarterly sales of $35.069 million which beat the analyst consensus estimate of $33.938 million by 3.33 percent. This is a 3.12 percent decrease over sales of $36.199 million the same period last year.

Global Medical REIT Q1 2024 FFO $0.23 Beats $0.21 Estimate, Sales $35.069M Beat $33.938M Estimate

Wednesday marks the last chance for investors to receive the next dividend payout from Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>). 
<h3>What's Happening</h3>
The company announced on Thursday that it would pay shareholders a quarterly dividend of 21 cents per share. On Thursday, Global Medical REIT will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 21 cents lower than it would have opened on any other day.
In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Thursday. Shareholders who own GMRE as of the end of Wednesday's session are eligible to receive the 21 cents dividend payout for every share that they own. 
According to the company, this dividend will be paid out to shareholders on April 09, 2024. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. 
To keep track of which companies are distributing dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.

Dividends

Global Medical REIT: Dividend Insights

Global Medical REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMRE#NYSE">GMRE</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.22 by 4.55 percent. The company reported quarterly sales of $32.93 million which missed the analyst consensus estimate of $35.64 million by 7.60 percent. This is a 9.26 percent decrease over sales of $36.29 million the same period last year.

Global Medical REIT Q4 2023 FFO $0.23 Beats $0.22 Estimate, Sales $32.93M Miss $35.64M Estimate

Comments

Global Medical REIT

Vendite allo scoperto

Global Medical REIT (NYSE:GMRE) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO